BIIB Biogen

  • Official Name: BIOGEN INC.
  • Headquarters: 225 Binney Street, CAMBRIDGE, MA, 02142 US
  • CEO: Christopher Viehbacher
  • Website: biogen.com

Match Results

Date League Week Opponent Result Score
2025-07-15 1R Won by 0.199 (2.871) - (3.070)
2025-07-18 1 Lost by 6.858 (5.609) - 1.249
2025-07-25 2 Lost by 5.743 4.549 - 10.292
2025-07-29 2R Lost by 2.129 (1.652) - 0.477
2025-08-01 3 Won by 6.740 0.635 - (6.105)
2025-08-07 1R Won by 0.254 (1.225) - (1.479)
2025-08-08 4 Lost by 14.390 1.196 - 15.586
2025-08-15 5 Lost by 1.151 5.113 - 6.264
2025-08-21 2R Lost by 0.219 0.103 - 0.322
2025-08-22 6 Lost by 0.017 1.483 - 1.500
2025-08-29 7 Lost by 2.894 (5.096) - (2.202)
2025-09-05 8 Won by 8.761 TOTW 5.971 - (2.790)
2025-09-12 9 Won by 3.263 TOTW 3.224 - (0.039)
2025-09-19 10 Lost by 4.358 (1.568) - 2.790
2025-09-26 11 Lost by 2.680 (3.463) - (0.783)
2025-10-03 12 Won by 15.386 13.959 - (1.427)
2025-10-10 13 Lost by 4.077 (8.310) - (4.233)
2025-10-17 14 Lost by 2.433 (2.474) - (0.041)
2025-10-24 15 Lost by 2.567 5.084 - 7.651

Latest News

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Yahoo - 2026-09-01

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) 🔗

BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring pro...

Benzinga - 2026-09-01

Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress 🔗

Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with R...

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
Yahoo - 2026-08-31

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease 🔗

An Important Step Forward for Access to LEQEMBI® for Eligible Patients in CanadaTOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai C...

Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks
Yahoo - 2026-08-30

Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks 🔗

In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ...

Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Yahoo - 2026-08-28

Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report? 🔗

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Show more
SeekingAlpha - 2026-07-15

Tau In The Clinic, Again 🔗